ArticleFrontiers in endocrinology2026
Early prediction of metastatic insulinoma using tumor size and biochemical markers: a retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Insulinomas are rare functional pancreatic neuroendocrine tumors. Metastasis is found in up to 15% of patients and is difficult to predict at diagnosis. Methods: We retrospectively analyzed 64 patients (56.2% female, median age 49 years) with biochemically confirmed insulinoma treated at a European Neuroendocrine Tumor Society Center of Excellence between 2010 and 2024, assessing clinical characteristics, tumor biology, diagnostics, treatments and survival (median follow-up 23 months) . Results: Metastasis was present in 27% of cases (17/64). Metastatic insulinomas had significantly larger primary tumors (median 32 vs. 15 mm, p < 0.001), higher Ki-67 indices (median 11% vs. 2%, p < 0.001), shorter overall survival (median 51 months vs. not reached, p < 0.001) and a shorter interval from symptom onset to diagnosis (median 2 vs. 8 months, p < 0.05). Surgery was performed in 79% of patients (39/45 non-metastatic vs. 10/17 metastatic insulinomas). All metastatic cases required further multimodal therapy, including pharmacological and local-ablative treatments. A logistic prediction model based on tumor size, fasting glucose and the insulin-to-C-peptide ratio was developed to predict metastasis in insulinoma patients and showed excellent performance (AUC 0.96, sensitivity 90.9%, specificity 93.8%) in the insulinoma cohort. ROC analysis identified clinically relevant size thresholds, with a tumor size cut-off at 19 mm capturing all metastatic insulinomas with available size data and a cut-off at 24 mm improving specificity for metastasis to 84.6%. Applied to 24 published insulinoma cases, the model achieved a classification accuracy of 75%. Stratification into three risk categories ("low," "medium," and "high") further enhanced clinical interpretability. In line with molecular studies, metastatic insulinomas in our cohort exhibited disproportionate proinsulin secretion in the available cases, supporting the concept of β-cell dedifferentiation with impaired prohormone processing as a feature of aggressive disease. Discussion: Our analysis highlights relevant clinical and biological distinctions between non-metastatic and metastatic insulinomas. Based on three diagnostic parameters, we propose a predictive model for early risk stratification to guide staging intensity and follow-up in insulinoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.